Healthcare Industry News: radiosurgery
News Release - May 27, 2010
First CyberKnife VSI System Installed at Creekside Cancer CareColorado Center to Offer Patients the Most Advanced radiosurgery Treatment Option
SUNNYVALE, Calif., May 27 (Healthcare Sales & Marketing Network) -- Accuray Incorporated (Nasdaq:ARAY ), a global leader in the field of radiosurgery, today announced the installation of the first CyberKnife VSI System at Creekside Cancer Care in Lafayette, Colo. The CyberKnife VSI System is the newest addition to the CyberKnife product family that will allow the Creekside Cancer Care center to offer expanded cancer treatment options from radiosurgery to high-precision radiation therapy. The center expects to begin treating patients with the CyberKnife VSI System in June.
The new CyberKnife VSI System brings important advantages that will allow the Creekside Cancer Care center to broaden the range of non-invasive treatment options they offer. The time to deliver a radiosurgery plan may be reduced by up to 50 percent, with no compromise in accuracy as is seen with hybrid radiotherapy systems. In fact, the CyberKnife VSI System has advanced the ability to track and correct for tumor motion; this is especially important for treating lung cancer, and allows a greater number of patients to be treated non-invasively. This combination of speed and accuracy is unique, allowing the CyberKnife VSI System to be used for procedures ranging from world class radiosurgery to Robotic Intensity Modulated Radiation Therapy (IMRT). Doctors at the Creekside Cancer Care center will be able to deliver highly precise radiation treatments over varying treatment sessions, or fractions, to customize their care to meet the unique needs of each patient.
"Unlike other radiotherapy or "hybrid" approaches, the CyberKnife VSI System gives us the most flexible and adaptive delivery possible utilizing 3-dimensional imaging and 6-dimensional tracking to detect tumor motion and to automatically correct for any changes in the patient or target position," said C. Kelley Simpson, M.D., of Creekside Cancer Care. "Our acquisition of the latest technology, the CyberKnife VSI, allows us to provide targeted robotic radiosurgery or radiation therapy in the most appropriate increments for each, individual patient. This allows us to better tailor our care to ensure the right amount of radiation is delivered to the right place in the right time frame for each patient, all with the same superior accuracy for which the CyberKnife is known."
"Centers like Creekside Cancer Care recognize and appreciate the opportunity that the CyberKnife VSI System presents to treat more patients, more effectively, and in the manner best suited for the patient," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The CyberKnife VSI System demonstrates our commitment and ability to continue the technological and clinical lead we've established in the radiation oncology field."
About Creekside Cancer Care
Creekside Cancer Care is a free-standing cancer care facility located in a scenic and tranquil creek side setting in the foothills of the Rocky Mountains in Lafayette, Colorado, just 30 minutes from Denver International Airport. Creekside Cancer Care boasts the most advanced clinical and health care information technologies available. The clinical focus of our extensively trained physicians and staff is to provide the best and most efficient patient centric care possible for the treatment of benign and malignant tumors throughout the body as well as functional neurological disorders. www.coloradocyberknife.com
About the CyberKnife® Robotic radiosurgery System
The CyberKnife Robotic radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq:ARAY ), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to deliver more than 80,000 treatments worldwide and currently 196 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to market need, clinical applications, and clinical acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2009 fiscal year, our quarterly report on Form 10-Q filed on May 6, 2010, and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsPhase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
Accuray and China Isotope and Radiation Corporation Enter Joint Venture Contract to Manufacture and Sell Radiation Oncology Systems in China
Accuray CyberKnife(R) System Treatment Delivery Times Up to 50 Percent Faster With Software Upgrade